JEROME COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021
Cancer Mortality 2018–2022
BRFSS 2011–2022

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and gene-environment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

RISK FACTORS AND INTERVENTIONS

Aging:
As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:
The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

Screening:
Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho
P.O. Box 1278
Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 522 cases of invasive cancer were diagnosed among Jerome County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Jerome County and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Jerome County	State of Idaho
All Sites/Types	**522**	**47,333**
Female Breast	**65**	**6,943**
Prostate	**64**	**6,766**
Lung & Bronchus	**54**	**4,959**
Colorectal	**48**	**3,632**

Table 3 (*Cancer Incidence 2017–2021, Comparison between Jerome County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Jerome County. The table also shows the number of observed cases, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Jerome County was 429.0 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (527.7) gives an estimate of the relative burden of disease in Jerome County.

The age- and sex-adjusted incidence rate of invasive cancer in Jerome County, all sites combined, was 497.4 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Jerome County (522) than expected (553.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 172 Jerome County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Jerome County and the State of Idaho, 2018–2022

Mortality 2018–2022	Jerome County	State of Idaho
All Deaths	**976**	**80,538**
Cancer Deaths	**172**	**15,233**
% of All Deaths	*17.6%*	*18.9%*
Lung & Bronchus	**29**	**2,937**
Colorectal	**20**	**1,332**
Pancreas	**9**	**1,190**
Female Breast	**13**	**1,111**
Prostate	**14**	**997**

Table 4 (*Cancer Mortality 2018–2022, Comparison between Jerome County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Jerome County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Jerome County, all sites combined, was 168.1 deaths per 100,000 persons per year during 2018–2022, compared with 165.7 for the remainder of the state. There were more cancer deaths in Jerome County (172) than expected (169.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution.
Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021
COMPARISON BETWEEN JEROME COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cancer Site/Type	Sex	Jerome County						Remainder of Idaho		
		Observed Cases	Person Years	Crude Rate (1)	A.A.I. Rate (1,2)	Expected Cases (3)	P-Value (4)	Observed Cases	Person Years	Crude Rate (1)
All Sites Combined	Total	522	121,678	429.0	497.4	553.8	0.182	46,811	8,870,428	527.7
All Sites Combined	Male	262	62,556	418.8	489.0	301.1	0.024 <<	25,008	4,449,717	562.0
All Sites Combined	Female	260	59,122	439.8	507.0	252.9	0.672	21,803	4,420,711	493.2
Bladder	Total	22	121,678	18.1	21.7	25.1	0.625	2,198	8,870,428	24.8
Bladder	Male	16	62,556	25.6	31.0	20.4	0.395	1,757	4,449,717	39.5
Bladder	Female	6	59,122	10.1	12.1	5.0	0.755	441	4,420,711	10.0
Brain - malignant	Total	6	121,678	4.9	5.4	8.1	0.598	651	8,870,428	7.3
Brain - malignant	Male	1	62,556	1.6	1.8	4.9	0.088	381	4,449,717	8.6
Brain - malignant	Female	5	59,122	8.5	9.3	3.3	0.469	270	4,420,711	6.1
Brain and other CNS - non-malignant	Total	6	121,678	4.9	5.6	18.6	0.001 <<	1,541	8,870,428	17.4
Brain and other CNS - non-malignant	Male	4	62,556	6.4	7.2	6.2	0.511	496	4,449,717	11.1
Brain and other CNS - non-malignant	Female	2	59,122	3.4	3.9	12.2	0.001 <<	1,045	4,420,711	23.6
Breast	Total	65	121,678	53.4	61.1	83.3	0.045 <<	6,943	8,870,428	78.3
Breast	Male	-	62,556	-	-	0.8	0.910	65	4,449,717	1.5
Breast	Female	65	59,122	109.9	126.4	80.0	0.098	6,878	4,420,711	155.6
Breast - in situ	Total	15	121,678	12.3	14.0	16.4	0.859	1,354	8,870,428	15.3
Breast - in situ	Male	-	62,556	-	-	0.1	1.000	4	4,449,717	0.1
Breast - in situ	Female	15	59,122	25.4	29.0	15.8	0.976	1,350	4,420,711	30.5
Cervix	Female	7	59,122	11.8	12.8	3.6	0.139	287	4,420,711	6.5
Colorectal	Total	48	121,678	39.4	45.5	42.6	0.448	3,584	8,870,428	40.4
Colorectal	Male	23	62,556	36.8	42.1	24.0	0.944	1,954	4,449,717	43.9
Colorectal	Female	25	59,122	42.3	49.0	18.8	0.196	1,630	4,420,711	36.9
Corpus Uteri	Female	22	59,122	37.2	42.8	15.5	0.138	1,332	4,420,711	30.1
Esophagus	Total	8	121,678	6.6	7.7	5.8	0.469	499	8,870,428	5.6
Esophagus	Male	7	62,556	11.2	13.1	5.1	0.498	422	4,449,717	9.5
Esophagus	Female	1	59,122	1.7	2.0	0.9	1.000	77	4,420,711	1.7
Hodgkin Lymphoma	Total	2	121,678	1.6	1.7	2.8	0.919	220	8,870,428	2.5
Hodgkin Lymphoma	Male	1	62,556	1.6	1.7	1.7	0.995	128	4,449,717	2.9
Hodgkin Lymphoma	Female	1	59,122	1.7	1.8	1.2	1.000	92	4,420,711	2.1
Kidney and Renal Pelvis	Total	18	121,678	14.8	17.0	23.1	0.343	1,933	8,870,428	21.8
Kidney and Renal Pelvis	Male	15	62,556	24.0	27.4	15.9	0.951	1,295	4,449,717	29.1
Kidney and Renal Pelvis	Female	3	59,122	5.1	5.9	7.4	0.127	638	4,420,711	14.4
Larynx	Total	5	121,678	4.1	4.8	2.5	0.224	215	8,870,428	2.4
Larynx	Male	4	62,556	6.4	7.5	2.0	0.271	163	4,449,717	3.7
Larynx	Female	1	59,122	1.7	2.0	0.6	0.898	52	4,420,711	1.2
Leukemia	Total	20	121,678	16.4	18.8	20.4	1.000	1,707	8,870,428	19.2
Leukemia	Male	10	62,556	16.0	18.3	12.6	0.577	1,026	4,449,717	23.1
Leukemia	Female	10	59,122	16.9	19.4	8.0	0.555	681	4,420,711	15.4
Liver and Bile Duct	Total	8	121,678	6.6	7.7	9.8	0.716	835	8,870,428	9.4
Liver and Bile Duct	Male	7	62,556	11.2	13.1	7.1	1.000	587	4,449,717	13.2
Liver and Bile Duct	Female	1	59,122	1.7	2.0	2.8	0.451	248	4,420,711	5.6
Lung and Bronchus	Total	54	121,678	44.4	53.1	56.2	0.836	4,905	8,870,428	55.3
Lung and Bronchus	Male	25	62,556	40.0	48.2	28.8	0.554	2,470	4,449,717	55.5
Lung and Bronchus	Female	29	59,122	49.1	58.2	27.4	0.817	2,435	4,420,711	55.1
Melanoma of the Skin	Total	45	121,678	37.0	42.4	37.0	0.225	3,099	8,870,428	34.9
Melanoma of the Skin	Male	28	62,556	44.8	51.9	22.6	0.307	1,867	4,449,717	42.0
Melanoma of the Skin	Female	17	59,122	28.8	32.6	14.5	0.581	1,232	4,420,711	27.9
Myeloma	Total	5	121,678	4.1	4.8	8.4	0.314	723	8,870,428	8.2
Myeloma	Male	4	62,556	6.4	7.5	5.3	0.785	443	4,449,717	10.0
Myeloma	Female	1	59,122	1.7	2.0	3.2	0.348	280	4,420,711	6.3
Non-Hodgkin Lymphoma	Total	23	121,678	18.9	21.9	23.4	1.000	1,969	8,870,428	22.2
Non-Hodgkin Lymphoma	Male	16	62,556	25.6	29.5	13.8	0.621	1,130	4,449,717	25.4
Non-Hodgkin Lymphoma	Female	7	59,122	11.8	13.8	9.7	0.505	839	4,420,711	19.0
Oral Cavity and Pharynx	Total	9	121,678	7.4	8.5	15.5	0.108	1,306	8,870,428	14.7
Oral Cavity and Pharynx	Male	3	62,556	4.8	5.5	11.6	0.006 <<	937	4,449,717	21.1
Oral Cavity and Pharynx	Female	6	59,122	10.1	11.8	4.2	0.506	369	4,420,711	8.3
Ovary	Female	11	59,122	18.6	21.3	6.3	0.116	542	4,420,711	12.3
Pancreas	Total	18	121,678	14.8	17.6	17.0	0.868	1,470	8,870,428	16.6
Pancreas	Male	8	62,556	12.8	15.2	9.7	0.747	818	4,449,717	18.4
Pancreas	Female	10	59,122	16.9	20.0	7.4	0.417	652	4,420,711	14.7
Prostate	Male	64	62,556	102.3	120.9	79.8	0.080	6,702	4,449,717	150.6
Stomach	Total	5	121,678	4.1	4.8	5.5	1.000	469	8,870,428	5.3
Stomach	Male	3	62,556	4.8	5.6	3.7	1.000	304	4,449,717	6.8
Stomach	Female	2	59,122	3.4	4.0	1.9	1.000	165	4,420,711	3.7
Testis	Male	5	62,556	8.0	8.1	3.7	0.641	269	4,449,717	6.0
Thyroid	Total	9	121,678	7.4	8.0	15.0	0.141	1,176	8,870,428	13.3
Thyroid	Male	3	62,556	4.8	5.3	4.7	0.609	369	4,449,717	8.3
Thyroid	Female	6	59,122	10.1	10.9	10.0	0.260	807	4,420,711	18.3
Pediatric Age 0 to 19	Total	5	39,939	12.5	12.6	6.8	0.665	420	2,459,385	17.1
Pediatric Age 0 to 19	Male	-	20,251	-	-	3.5	0.063	214	1,254,070	17.1
Pediatric Age 0 to 19	Female	5	19,688	25.4	26.0	3.3	0.470	206	1,205,315	17.1

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018–2022
COMPARISON BETWEEN JEROME COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cause of Death Cancer Site/Type	Sex	Jerome County						Remainder of Idaho		
		Observed Deaths	Person Years	Crude Rate (1)	A.A.M. Rate (1,2)	Expected Deaths (3)	P-Value (4)	Observed Deaths	Person Years	Crude Rate (1)
All Causes of Death	Total	976	123,198	792.2	956.9	892.8	0.006 >>	79,559	9,088,196	875.4
All Causes of Death	Male	538	63,505	847.2	1,012.8	491.7	0.041 >>	42,248	4,564,192	925.6
All Causes of Death	Female	438	59,693	733.8	892.8	404.6	0.105	37,311	4,524,004	824.7
All Malignant Cancers	Total	172	123,198	139.6	168.1	169.6	0.873	15,061	9,088,196	165.7
All Malignant Cancers	Male	84	63,505	132.3	160.1	93.7	0.342	8,151	4,564,192	178.6
All Malignant Cancers	Female	88	59,693	147.4	176.3	76.2	0.201	6,910	4,524,004	152.7
Bladder	Total	4	123,198	3.2	4.1	5.2	0.804	481	9,088,196	5.3
Bladder	Male	4	63,505	6.3	7.9	4.1	1.000	371	4,564,192	8.1
Bladder	Female	-	59,693	-	-	1.2	0.620	110	4,524,004	2.4
Brain and Other Nervous System	Total	4	123,198	3.2	3.7	6.1	0.544	514	9,088,196	5.7
Brain and Other Nervous System	Male	-	63,505	-	-	3.5	0.058	289	4,564,192	6.3
Brain and Other Nervous System	Female	4	59,693	6.7	7.7	2.6	0.520	225	4,524,004	5.0
Breast	Total	13	123,198	10.6	12.5	12.7	1.000	1,111	9,088,196	12.2
Breast	Male	-	63,505	-	-	0.2	1.000	13	4,564,192	0.3
Breast	Female	13	59,693	21.8	25.9	12.2	0.892	1,098	4,524,004	24.3
Cervix	Female	1	59,693	1.7	1.9	1.0	1.000	87	4,524,004	1.9
Colorectal	Total	20	123,198	16.2	19.2	15.0	0.252	1,312	9,088,196	14.4
Colorectal	Male	9	63,505	14.2	16.6	8.6	0.984	723	4,564,192	15.8
Colorectal	Female	11	59,693	18.4	22.0	6.5	0.134	589	4,524,004	13.0
Corpus Uteri	Female	6	59,693	10.1	12.1	1.8	0.020 >>	163	4,524,004	3.6
Esophagus	Total	6	123,198	4.9	5.8	5.2	0.826	455	9,088,196	5.0
Esophagus	Male	6	63,505	9.4	11.3	4.5	0.589	385	4,564,192	8.4
Esophagus	Female	-	59,693	-	-	0.8	0.923	70	4,524,004	1.5
Hodgkin Lymphoma	Total	1	123,198	0.8	1.0	0.3	0.483	24	9,088,196	0.3
Hodgkin Lymphoma	Male	-	63,505	-	-	0.2	1.000	14	4,564,192	0.3
Hodgkin Lymphoma	Female	1	59,693	1.7	1.9	0.1	0.215	10	4,524,004	0.2
Kidney	Total	3	123,198	2.4	3.0	4.3	0.768	383	9,088,196	4.2
Kidney	Male	3	63,505	4.7	5.7	2.8	1.000	243	4,564,192	5.3
Kidney	Female	-	59,693	-	-	1.5	0.441	140	4,524,004	3.1
Larynx	Total	1	123,198	0.8	1.0	0.9	1.000	75	9,088,196	0.8
Larynx	Male	1	63,505	1.6	1.9	0.7	1.000	64	4,564,192	1.4
Larynx	Female	-	59,693	-	-	0.1	1.000	11	4,524,004	0.2
Leukemia	Total	4	123,198	3.2	3.9	7.4	0.279	661	9,088,196	7.3
Leukemia	Male	3	63,505	4.7	5.7	4.5	0.683	394	4,564,192	8.6
Leukemia	Female	1	59,693	1.7	2.0	2.9	0.419	267	4,524,004	5.9
Liver and Bile Duct	Total	3	123,198	2.4	2.9	7.2	0.146	632	9,088,196	7.0
Liver and Bile Duct	Male	2	63,505	3.1	3.8	4.9	0.264	421	4,564,192	9.2
Liver and Bile Duct	Female	1	59,693	1.7	2.0	2.3	0.645	211	4,524,004	4.7
Lung and Bronchus	Total	29	123,198	23.5	28.6	32.5	0.619	2,908	9,088,196	32.0
Lung and Bronchus	Male	14	63,505	22.0	26.9	17.4	0.501	1,527	4,564,192	33.5
Lung and Bronchus	Female	15	59,693	25.1	30.3	15.1	1.000	1,381	4,524,004	30.5
Melanoma of the Skin	Total	4	123,198	3.2	3.8	3.4	0.887	297	9,088,196	3.3
Melanoma of the Skin	Male	3	63,505	4.7	5.6	2.3	0.813	197	4,564,192	4.3
Melanoma of the Skin	Female	1	59,693	1.7	2.0	1.1	1.000	100	4,524,004	2.2
Myeloma	Total	1	123,198	0.8	1.0	3.6	0.255	324	9,088,196	3.6
Myeloma	Male	1	63,505	1.6	2.0	2.1	0.759	187	4,564,192	4.1
Myeloma	Female	-	59,693	-	-	1.5	0.447	137	4,524,004	3.0
Non-Hodgkin Lymphoma	Total	9	123,198	7.3	8.8	6.3	0.361	559	9,088,196	6.2
Non-Hodgkin Lymphoma	Male	4	63,505	6.3	7.6	3.5	0.937	306	4,564,192	6.7
Non-Hodgkin Lymphoma	Female	5	59,693	8.4	10.2	2.8	0.291	253	4,524,004	5.6
Oral Cavity and Pharynx	Total	2	123,198	1.6	1.9	3.1	0.799	273	9,088,196	3.0
Oral Cavity and Pharynx	Male	1	63,505	1.6	1.9	2.2	0.695	191	4,564,192	4.2
Oral Cavity and Pharynx	Female	1	59,693	1.7	2.0	0.9	1.000	82	4,524,004	1.8
Ovary	Female	6	59,693	10.1	12.0	3.9	0.409	355	4,524,004	7.8
Pancreas	Total	9	123,198	7.3	8.8	13.3	0.299	1,181	9,088,196	13.0
Pancreas	Male	2	63,505	3.1	3.8	7.4	0.043 <<	648	4,564,192	14.2
Pancreas	Female	7	59,693	11.7	14.1	5.9	0.741	533	4,524,004	11.8
Prostate	Male	14	63,505	22.0	27.8	10.9	0.412	983	4,564,192	21.5
Stomach	Total	2	123,198	1.6	1.9	2.2	1.000	192	9,088,196	2.1
Stomach	Male	-	63,505	-	-	1.4	0.491	119	4,564,192	2.6
Stomach	Female	2	59,693	3.4	3.9	0.8	0.402	73	4,524,004	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Jerome County
Access to Care									
Have Health Insurance, Age < 65 (2021–2022)	90.0%	89.3%	87.8%	86.4%	92.6%	87.2%	89.1%	92.6%	72.0%
Not See Doctor Due to Cost in Past Year (2020–2022)	10.4%	9.5%	11.0%	11.0%	10.2%	10.2%	10.4%	11.3%	9.9%
Cancer Screening									
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years)	62.9%	61.0%	70.0%	60.3%	66.1%	58.9%	61.0%	62.5%	56.1%
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.1%	73.7%	73.6%	70.9%	72.9%	69.4%	69.3%	65.5%	.
Colorectal Cancer Screening, Age 45–75 (2022)	63.3%	61.0%	62.5%	60.8%	67.2%	65.0%	60.4%	60.2%	.
Tobacco Use									
Current Tobacco User (2020–2022)	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	19.7%
Other Cancer-Related									
Healthy Weight by Body Mass Index, Age 20+ (2020–2022)	30.0%	30.0%	30.1%	26.5%	33.7%	27.5%	26.7%	30.2%	21.5%
Any Physical Activity Besides Job Past 30 Days (2018–2022)	79.1%	79.0%	78.0%	75.4%	82.7%	75.2%	76.7%	81.0%	71.1%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	22.0%	22.8%	19.2%	20.0%	25.2%	19.5%	20.4%	20.3%	14.4%
Home Ever Tested for Radon (2016, 2018, 2020)	22.9%	30.8%	18.3%	16.9%	25.2%	20.1%	23.0%	21.0%	13.3%

Access to Care

Have Health Insurance – 2021–2022
Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year – 2020–2022
Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than $15,000, 5.8% for greater than $50,000).

Cancer Screening

Mammogram – 2014–2022, even years
Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

Pap Test – 2018, 2020
Statewide, 71.1% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening – 2022
Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Cancer Screening and Risk Factors

Tobacco Use

Current Tobacco Use – 2020–2022
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index – 2020–2022
Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity – 2018-2022
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019
Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing – 2016, 2018, 2020
Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

CDRI Cancer Data Registry of Idaho

Idaho Hospital Association